Probing characteristics of cancer cells cultured on engineered platforms simulating different microenvironments

References

• Rodriguez-Devora JI, Zhang BM, Reyna D, et al. High throughput miniature drug-screening platform using bioprinting technology. Biofabrication. 2012 Sep;4. DOI:https://doi.org/10.1088/1758-5082/4/3/035001
   Google Scholar
• DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ. 2003;22:151–185.
   PubMed Web of Science ®Google Scholar
• DiMasi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical industry: new estimates of R&D costs. J Health Econ. 2016;47:20–33.
   PubMed Web of Science ®Google Scholar
• Akhtar AZ, Pippin JJ, Sandusky CB. Animal studies in spinal cord injury: a systematic review of methylprednisolone. Altern Lab Anim. 2009;37:43–62.
   PubMed Web of Science ®Google Scholar
• Burgon J, Hamerslag L. The relationship between scientific research, clinical trials and FDA drug approval. Value Health. 2013;16:A478–A47A.
   Web of Science ®Google Scholar
• Taylor K, Gordon N, Langley G, et al. Estimates for worldwide laboratory animal use in 2005: authors' response. Atla-Altern Lab Anim. 2008;36:496–497.
   Web of Science ®Google Scholar
• Hay M, Thomas DW, Craighead JL, et al. Clinical development success rates for investigational drugs. Nat Biotechnol. 2014;32:40–51.
   PubMed Web of Science ®Google Scholar
• DiMasi JA, Feldman L, Seckler A, et al. Trends in risks associated with new drug development: success rates for investigational drugs. Clin Pharmacol Ther. 2010;87:272–277.
   PubMed Web of Science ®Google Scholar
• Kaitin KI, DiMasi JA. Pharmaceutical innovation in the 21st century: new drug approvals in the first decade, 2000-2009. Clin Pharmacol Ther. 2011;89:183–188.
   PubMed Web of Science ®Google Scholar
• Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov. 2004;3:711–715.
   PubMed Web of Science ®Google Scholar
• Akhtar A. The flaws and human harms of animal experimentation. Camb Q Healthc Ethics. 2015;24:407–419.
   PubMed Web of Science ®Google Scholar
• Ledford H. Translational research: 4 ways to fix the clinical trial. Nature. 2011;477:526–528.
   PubMed Web of Science ®Google Scholar
• Arrowsmith J. Trial watch: phase III and submission failures: 2007-2010. Nat Rev Drug Discov. 2011;10:87.
   PubMed Web of Science ®Google Scholar
• Mak IWY, Evaniew N, Ghert M. Lost in translation: animal models and clinical trials in cancer treatment. Am J Transl Res. 2014;6:114–118.
   PubMed Web of Science ®Google Scholar
• Curt GA, Chabner BA. One in five cancer clinical trials is published: a terrible symptom-what's the diagnosis? Oncologist. 2008;13:923–924.
   PubMed Web of Science ®Google Scholar
• Pattabiraman DR, Weinberg RA. Tackling the cancer stem cells – what challenges do they pose?. Nat Rev Drug Discov. 2014;13:497–512.
   PubMed Web of Science ®Google Scholar
• Joyce JA. Therapeutic targeting of the tumor microenvironment. Cancer Cell. 2005;7:513–520.
   PubMed Web of Science ®Google Scholar
• Stringfellow DA, Gray BW, Lauerman LH, et al. Monolayer culture of cells originating from a preimplantation bovine embryo. In Vitro Cell Dev Biol. 1987;23:750–754.
   PubMed Web of Science ®Google Scholar
• Li Y, Killian KA. Bridging the Gap: from 2D cell culture to 3D microengineered extracellular matrices. Adv Healthc Mater. 2015;4:2780–2796.
   Web of Science ®Google Scholar
• Whitesides GM. The origins and the future of microfluidics. Nature. 2006;442:368–373.
   PubMed Web of Science ®Google Scholar
• Wu MH, Huang SB, Lee GB. Microfluidic cell culture systems for drug research. Lab Chip. 2010;10:939–956.
   PubMed Web of Science ®Google Scholar
• Holle AW, Young JL, Spatz JP. In vitro cancer cell-ECM interactions inform in vivo cancer treatment. Adv Drug Deliv Rev. 2016;97:270–279.
   PubMed Web of Science ®Google Scholar
• Li H, Fan X, Houghton J. Tumor microenvironment: the role of the tumor stroma in cancer. J Cell Biochem. 2007;101:805–815.
   PubMed Web of Science ®Google Scholar
• Landowski TH, Olashaw NE, Agrawal D, et al. Cell adhesion-mediated drug resistance (CAM-DR) is associated with activation of NF-kappa B (RelB/p50) in myeloma cells. Oncogene. 2003;22:2417–2421.
   PubMed Web of Science ®Google Scholar
• Mbeunkui F, Johann DJ. Cancer and the tumor microenvironment: a review of an essential relationship. Cancer Chemother Pharmacol. 2009;63:571–582.
   PubMed Web of Science ®Google Scholar
• Whiteside TL. The tumor microenvironment and its role in promoting tumor growth. Oncogene. 2008;27:5904–5912.
   PubMed Web of Science ®Google Scholar
• Cox MC, Reese LM, Bickford LR, et al. Toward the broad adoption of 3D tumor models in the cancer drug pipeline. Acs Biomater Sci Eng. 2015;1:877–894.
   PubMed Web of Science ®Google Scholar
• Mehta G, Hsiao AY, Ingram M, et al. Opportunities and challenges for use of tumor spheroids as models to test drug delivery and efficacy. J Control Release. 2012;164:192–204.
   PubMed Web of Science ®Google Scholar
• Chen QM, Kinch MS, Lin TH, et al. Integrin-mediated cell-adhesion activates mitogen-activated protein-kinases. J Biol Chem. 1994;269:26602–26605.
   PubMed Web of Science ®Google Scholar
• Kim HN, Jang KJ, Shin JY, et al. Artificial slanted nanocilia array as a mechanotransducer for controlling cell polarity. ACS Nano. 2017;11:730–741.
   PubMed Web of Science ®Google Scholar
• Matsunaga T, Takemoto N, Sato T, et al. Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia. Nat Med. 2003;9:1158–1165.
   PubMed Web of Science ®Google Scholar
• Hughes CS, Postovit LM, Lajoie GA. Matrigel: a complex protein mixture required for optimal growth of cell culture. Proteomics. 2010;10:1886–1890.
   PubMed Web of Science ®Google Scholar
• Perche F, Torchilin VP. Cancer cell spheroids as a model to evaluate chemotherapy protocols. Cancer. Biol Ther. 2012;13:1205–1213.
   Google Scholar
• Desoize B, Jardillier J. Multicellular resistance: a paradigm for clinical resistance? Crit Rev Oncol Hematol. 2000;36:193–207.
   PubMed Web of Science ®Google Scholar
• El Bayoumil T, Torchilin VP. Tumor-targeted nanomedicines: enhanced antitumor efficacy in vivo of doxorubicin-loaded, long-circulating liposomes modified with cancer-specific monoclonal antibody. Clin Cancer Res. 2009;15:1973–1980.
   PubMed Web of Science ®Google Scholar
• Le VM, Lang MD, Shi WB, et al. A collagen-based multicellular tumor spheroid model for evaluation of the efficiency of nanoparticle drug delivery. Artif Cells Nanomed Biotechnol. 2016;44:540–544.
   PubMed Web of Science ®Google Scholar
• Safdar MH, Hussain Z, Abourehab MAS, et al. New developments and clinical transition of hyaluronic acid-based nanotherapeutics for treatment of cancer: reversing multidrug resistance, tumour-specific targetability and improved anticancer efficacy. Artif Cells Nanomed Biotechnol 2017 [Oct 30]:[14 p.]. DOI:https://doi.org/10.1080/21691401.2017.1397001
   Google Scholar
• Usmani A, Mishra A, Ahmad M. Nanomedicines: a theranostic approach for hepatocellular carcinoma. Artif Cells Nanomed Biotechnol. 2017 [Sep 8]:[11 p.]. DOI:https://doi.org/10.1080/21691401.2017.1374282
   Google Scholar
• Goodman TT, Olive PL, Pun SH. Increased nanoparticle penetration in collagenase-treated multicellular spheroids. Int J Nanomedicine. 2007;2:265–274.
   PubMed Web of Science ®Google Scholar
• Albanese A, Lam AK, Sykes EA, et al. Tumour-on-a-chip provides an optical window into nanoparticle tissue transport. Nat Comms. 2013;4:2718.
   PubMed Web of Science ®Google Scholar
• Wilson WR, Hay MP. Targeting hypoxia in cancer therapy. Nat Rev Cancer. 2011;11:393–410.
   PubMed Web of Science ®Google Scholar
• Martin TA, Jiang WG. Loss of tight junction barrier function and its role in cancer metastasis. Biochim Biophys Acta. 2009;1788:872–891.
   PubMed Web of Science ®Google Scholar
• Panksepp J. Affective preclinical modeling of psychiatric disorders: taking imbalanced primal emotional feelings of animals seriously in our search for novel antidepressants. Dialogues Clin Neuro. 2015;17:363–379.
   PubMed Web of Science ®Google Scholar
• Akhtar A. Animals and public health: why treating animals better is critical to human welfare. Choice: Curr Rev Acad Libraries 2012;50:515.
   Google Scholar
• Greek R, Menache A. Systematic reviews of animal models: methodology versus epistemology. Int J Med Sci. 2013;10:206–221.
   PubMed Web of Science ®Google Scholar
• Ehrmann RL, Gey GO. The growth of cells on a transparent gel of reconstituted rat-tail collagen. J Natl Cancer Inst. 1956;16:1375–1403.
   PubMed Web of Science ®Google Scholar
• Bhatia SN, Ingber DE. Microfluidic organs-on-chips. Nat Biotechnol. 2014;32:760–772.
   PubMed Web of Science ®Google Scholar
• DiMasi JA, Hansen RW, Grabowski HG, et al. Cost of innovation in the pharmaceutical industry. J Health Econ. 1991;10:107–142.
   PubMed Web of Science ®Google Scholar